Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110175574> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2110175574 endingPage "1771" @default.
- W2110175574 startingPage "1767" @default.
- W2110175574 abstract "Background: Darbepoetin alfa, has a longer half- life than epoetin alfa (rHuEPO) due to its increased sialylated carbohydrate content and can be administered less frequently. Its advantage in terms of response is not entirely clear. Patients and Methods: From August 2005 until October 2006, 64 anemic patients (hemoglobin ≤11.5 g/dl) with advanced metastatic cancer receiving chemotherapy (CT), median age 65 years (range 33-77), median Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (range 0-1), were treated with subcutaneous (s.c.) darbepoetin alfa 500 μg every 3 weeks(Q3W) and a single intravenous (i.v.) dose of 125 mg of elemental iron at the beginning of the treatment period followed by an oral daily iron supplement (200 mg of elementary iron). The treatment effect was evaluated as a response (Hb increase ≥1 g/dl) or a major response (Hb increase ≥2 g/dl) after 2, 4, 6 and 8 weeks . The patients were questioned about fatigue. Results: After 8 weeks of treatment, a treatment response was observed in 11 out of the 29 evaluable patients (38% ) with a major response in 10% . The mean Hb change was 0 g/dl, +0.9 g/dl, +0.75 g/dl and +0.7 g/dl respectively at 2, 4, 6 and 8 weeks. Blood transfusions were required in 9 patients (31% ). At baseline, 39 out of the 64 patients (61% ) reported grade 1 or 2 fatigue. At 8 weeks the patients with a major response did not show any evidence of fatigue. Conclusion: Darbepoetin alfa Q3W is moderately effective in reducing anemia in heavily pretreated and advanced stage chemotherapy treated patients." @default.
- W2110175574 created "2016-06-24" @default.
- W2110175574 creator A5009508595 @default.
- W2110175574 creator A5009580959 @default.
- W2110175574 creator A5011655337 @default.
- W2110175574 creator A5065833805 @default.
- W2110175574 creator A5068321284 @default.
- W2110175574 creator A5073193449 @default.
- W2110175574 creator A5091509029 @default.
- W2110175574 date "2008-05-01" @default.
- W2110175574 modified "2023-10-04" @default.
- W2110175574 title "Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT)." @default.
- W2110175574 cites W2070676669 @default.
- W2110175574 cites W2073426798 @default.
- W2110175574 cites W2148037225 @default.
- W2110175574 cites W2159754564 @default.
- W2110175574 cites W2442528111 @default.
- W2110175574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18630457" @default.
- W2110175574 hasPublicationYear "2008" @default.
- W2110175574 type Work @default.
- W2110175574 sameAs 2110175574 @default.
- W2110175574 citedByCount "1" @default.
- W2110175574 countsByYear W21101755742016 @default.
- W2110175574 crossrefType "journal-article" @default.
- W2110175574 hasAuthorship W2110175574A5009508595 @default.
- W2110175574 hasAuthorship W2110175574A5009580959 @default.
- W2110175574 hasAuthorship W2110175574A5011655337 @default.
- W2110175574 hasAuthorship W2110175574A5065833805 @default.
- W2110175574 hasAuthorship W2110175574A5068321284 @default.
- W2110175574 hasAuthorship W2110175574A5073193449 @default.
- W2110175574 hasAuthorship W2110175574A5091509029 @default.
- W2110175574 hasConcept C121608353 @default.
- W2110175574 hasConcept C126322002 @default.
- W2110175574 hasConcept C141071460 @default.
- W2110175574 hasConcept C2776164570 @default.
- W2110175574 hasConcept C2776694085 @default.
- W2110175574 hasConcept C2778248108 @default.
- W2110175574 hasConcept C2778917026 @default.
- W2110175574 hasConcept C2781404941 @default.
- W2110175574 hasConcept C71924100 @default.
- W2110175574 hasConcept C90924648 @default.
- W2110175574 hasConceptScore W2110175574C121608353 @default.
- W2110175574 hasConceptScore W2110175574C126322002 @default.
- W2110175574 hasConceptScore W2110175574C141071460 @default.
- W2110175574 hasConceptScore W2110175574C2776164570 @default.
- W2110175574 hasConceptScore W2110175574C2776694085 @default.
- W2110175574 hasConceptScore W2110175574C2778248108 @default.
- W2110175574 hasConceptScore W2110175574C2778917026 @default.
- W2110175574 hasConceptScore W2110175574C2781404941 @default.
- W2110175574 hasConceptScore W2110175574C71924100 @default.
- W2110175574 hasConceptScore W2110175574C90924648 @default.
- W2110175574 hasLocation W21101755741 @default.
- W2110175574 hasLocation W21101755742 @default.
- W2110175574 hasOpenAccess W2110175574 @default.
- W2110175574 hasPrimaryLocation W21101755741 @default.
- W2110175574 hasRelatedWork W1972295121 @default.
- W2110175574 hasRelatedWork W1984599916 @default.
- W2110175574 hasRelatedWork W2001073112 @default.
- W2110175574 hasRelatedWork W2014883501 @default.
- W2110175574 hasRelatedWork W2024280247 @default.
- W2110175574 hasRelatedWork W2047254033 @default.
- W2110175574 hasRelatedWork W2060869681 @default.
- W2110175574 hasRelatedWork W2061764566 @default.
- W2110175574 hasRelatedWork W2070676669 @default.
- W2110175574 hasRelatedWork W2148037225 @default.
- W2110175574 hasRelatedWork W2155924342 @default.
- W2110175574 hasRelatedWork W2164837040 @default.
- W2110175574 hasRelatedWork W2169321604 @default.
- W2110175574 hasRelatedWork W2243116758 @default.
- W2110175574 hasRelatedWork W2531926824 @default.
- W2110175574 hasRelatedWork W2550060034 @default.
- W2110175574 hasRelatedWork W2581782466 @default.
- W2110175574 hasRelatedWork W2595770802 @default.
- W2110175574 hasRelatedWork W1960769632 @default.
- W2110175574 hasRelatedWork W2123693381 @default.
- W2110175574 hasVolume "28" @default.
- W2110175574 isParatext "false" @default.
- W2110175574 isRetracted "false" @default.
- W2110175574 magId "2110175574" @default.
- W2110175574 workType "article" @default.